↓
Why is it important to have effective Chronic Myeloid Leukemia Monitoring?

 

Treatment access is giving a lifeline to someone who has been diagnosed with cancer. Watch this video and learn how importance of CML Monitoring changes patients' lives.

 

What is CML?

Affects immature myeloid cells in the bone marrow, impeding their normal differentiation into red blood cells, platelets, and some white blood cell types.1

15%

of all leukemias in adults2

affects adults who are older than

643

>95%

CML patients survive more than 5 years after their initial diagnosis4

CML is linked to a genetic mutation - the Philadelphia Chromosome

>95%

Cases are either e13a2 or e14a25 

<1%

rare BCR-ABL1 transcripts are occasionally observed5 

United States

Prevalence is predicted to double from 2010 – 20307

8,990

Estimated new CML cases in 20193

Europe

people

10-12

per 100,000 inhabitants6

heart

Steady increase in CML patients is due to dramatic improvements in survival6

6,370

Estimated new CML cases per year1

Global

0.4

Incidence rate in Africa8

0.4

Incidence rate in Latin America8

0.7-1.2

Incidence rate in Asia Pacific8

How to treat CML?

Current NCCN guidelines

The monitoring test should report on the International Scale (%IS) and be repeated four times a year.9

 

pill

Treatment
TKI Inhibitors

xpress

Monitoring
Sensitive and quantitative monitoring of BCR-ABL mRNA
in patients with CML

 

 

The Importance of Monitoring

There is a greater need for fast and sensitive molecular diagnostic testing to support timely treatment decisions10

40-60%

of CML patients, if regularly monitored, can be eligible for treatment discontinuation10

95%

of CML patients who stopped treatment relapse within 7 months of treatment cessation10

 

CML Monitoring Solution

Xpert® BCR-ABL Ultra

provides a sensitive and quantitative
monitoring of BCR-ABL major breakpoint (p210) transcripts in patients with CML

* IVD. In Vitro Diagnostic Medical Device. May not be available in all countries

References
  1. Hoffmann, V., Baccarani, M., Hasford, J. et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia 29, 1336–1343 (2015). https://doi.org/10.1038/leu.2015.73
  2. Chronic myeloid leukemia: Topics. Cancer Network. (n.d.). Retrieved November 23, 2021, from https://www.cancernetwork.com/clinical/chronic-myeloid-leukemia
  3. Key Statistics for Chronic Myeloid Leukemia. (2021). Retrieved 23 November 2021, from https://www.cancer.org/cancer/chronic-myeloid-leukemia/about/statistics.html
  4. Kantarjian H et al. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol. 2011;29(23):3173-8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874216/pdf/zlj3173.pdf
  5. Zagaria, A., Anelli, L., Coccaro, N., Tota, G., Casieri, P., Cellamare, A., Impera, L., Brunetti, C., Minervini, A., Minervini, C. F., Delia, M., Cumbo, C., Orsini, P., Specchia, G., & Albano, F. (2015). BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR. Virchows Archiv : an international journal of pathology, 467(3), 357–363. https://doi.org/10.1007/s00428-015-1802-z
  6. Hoglund M et al. Epidemiology of chronic myeloid leukemia: an update. Ann Hematol. 2015 Apr;94(2):241-7. https://www.ncbi.nlm.nih.gov/pubmed/25814090
  7. Xuelin H et al. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Amer Can Soc. 2012 Jun 15;118(12):3123-3127. https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.26679
  8. Tadwalkar S. The global incidence and prevalence of chronic myeloid leukemia over the next ten years (2017-2027). 2017 Jul 01. Bangkok. Thailand. https://www.omicsonline.org/proceedings/the-global-incidence-and-prevalence-of-chronic-myeloid-leukemia-over-the-next-ten-years-20172027-71073.html
  9. NCCN. Chronic Myeloid Leukemia. Accessed Nov 23 2021. http://research.fhcrc.org/content/dam/stripe/lymphoma-tumor-board/publications/NCCN%20Guidelines%20-%20CML.pdf
  10. Goldberg S et al. Considerations for Successful Treatment-free Remission in Chronic Myeloid Leukemia. Clin Lymph, Myel & Leuk. 2017; 18(2):98-105. https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(17)30991-6/fulltext.
Speak to an Expert

In submitting this form, you agree to be contacted by Cepheid to receive information on products, goods, and services, which may include similar products, goods, or services from our affiliates. Consent may be withdrawn at any time. For additional information about how we handle your personal data, please review our online privacy policy.